No Data
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 Loss per Share (Vs US$1.01 Loss in 3Q 2023)
Citi Maintains Crinetics(CRNX.US) With Buy Rating, Raises Target Price to $74
JonesTrading Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $71
Express News | Crinetics Pharmaceuticals Inc : Leerink Partners Raises Target Price to $80 From $63
Piper Sandler Maintains Crinetics(CRNX.US) With Buy Rating, Maintains Target Price $97
No Data
No Data